Juan Sarmiento, MD
Endocrinology, Diabetes & Metabolism · Raceland, LANPI 1942652482
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Dexcom, Inc. at 34.9% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in LA, where the typical reported total is $3,044.
Across 94 payments — averaging $29.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$970
- Novo Nordisk$507
- Lilly USA, LLC$221
- Medtronic$178
- Mannkind Corporation$133
- Insulet Corporation$132
- plus $637 from 9 others
What the payments were for
- Food & beverage$2,58093%
- Education$1385%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 35 | $970 |
| Novo Nordisk | 26 | $507 |
| Lilly USA, LLC | 9 | $221 |
| Medtronic(2 entities) | 3 | $178 |
| Mannkind Corporation | 3 | $133 |
| Insulet Corporation | 5 | $132 |
| AstraZeneca | 1 | $132 |
| Bayer | 2 | $129 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Amgen | 1 | $106 |
| Corcept Therapeutics | 3 | $66 |
| Boehringer Ingelheim | 2 | $33 |
| Sequel Med Tech, LLC | 1 | $25 |
| Abbott | 1 | $16 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$230
- FARXIGA$132
- DEXCOM G6 CGM SYSTEM$126
- NEXLIZET$125
- NEXLETOL$125
- DEXCOM G7 GSS (161)$117
- Kerendia$111
- Prolia$106
- RYBELSUS$104
How this compares
$2,777 in reported general payments places this provider in the 45th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 547 | $598,518 |
| MounjaroTirzepatide | 356 | $466,622 |
| JardianceEmpagliflozin | 299 | $272,239 |
| TrulicityDulaglutide | 134 | $154,905 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 79 | $64,284 |
| FarxigaDapagliflozin Propanediol | 42 | $31,686 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $28,295 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $24,396 |
| TradjentaLinagliptin | 29 | $23,262 |
| XyostedTestosterone Enanthate | 35 | $21,732 |
| RybelsusSemaglutide | 12 | $16,381 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $14,879 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $13,799 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 13 | $9,943 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 19 | $9,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $507 | $630,970591 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $221 | $626,331542 claims |
| Boehringer IngelheimJardiance, Tradjenta | $33 | $295,500328 claims |
| AstraZenecaFarxiga | $132 | $31,68642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Raceland
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
- Harold MillerHammond$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.